On Oct. 5, Pfizer announced that Abrilada (adalimumab-afzb), its biosimilar to Humira (adalimumab), had received an interchangeable designation from the U.S. Food & Drug Administration (FDA).
Cannabis for Pain Relief: An Area Ripe for Research
Medical cannabis may benefit patients experiencing pain, and rheumatologists should be able to discuss its potential risks and benefits with their patients. Here are insights from Dr. Mary Ann Fitzcharles on current research, patient use and more.
Glucocorticoid Use at Any Dose Increases Fracture Risk
The accepted wisdom is that the negative effects of glucocorticoids on bone depend on the dose and treatment duration. Adami et al. conducted this study to determine, in a real-life setting, the risk of fragility fracture associated with the dose of glucocorticoids in patients with inflammatory rheumatic musculoskeletal diseases.
Findings from a Clinical Trial of Dazodalibep for Sjögren’s Disease
St.Clair et al. found that patients with Sjögren’s disease treated with dazodalibep experienced greater improvement in key symptoms of dryness, fatigue and pain than patients who received placebo.
Investigational Nanobody Compound Shows Promise for RA Treatment
In Japan, ozoralizumab will soon be available as a 30 mg subcutaneous auto-injection to treat patients with rheumatoid arthritis.
Marching to the Biosimilar Beat: Questions on Rollout Remain
The availability of biosimilars for the treatment of patients with rheumatic diseases exploded in 2023. Here’s where we stand and what to expect going forward.
A Novel Study Compared the Effectiveness of Adalimumab with Tofacitinib in RA
Your patient with rheumatoid arthritis (RA) isn’t responding well enough to methotrexate, and you both agree it’s time to consider a biologic or targeted synthetic disease-modifying anti-rheumatic drug (DMARD). But which one should you choose? In a treat-to-target era, we’re fortunate to have a variety of RA therapies at our disposal. Clinical practice guidelines from…
Do NSAIDs Mask MRI Findings in Patients with Axial Spondyloarthritis?
Research suggests the use of non-steroidal anti-inflammatory drugs may mask the amount of sacroiliac joint inflammation found on MRI in patients with axial spondyloarthritis.
A Dual Inhibitor Treatment for RA?
TLL-018, a Janus kinase 1/tyrosine kinase 2 inhibitor, proved more effective for treating patients with RA than tofacitinib, according to a study by Zeng et al.
Many Medications: Understanding the Biologic Management of Psoriasis
ORLANDO, FLORIDA — Given the intersection between rheumatology and dermatology for many patients with autoimmune diseases, it’s helpful to hear from specialists in both fields regarding disease management strategies.
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- …
- 123
- Next Page »